Contents

List of Table and Figures \hspace{1cm} \textbf{page} \hspace{1cm} ix
Acknowledgments \hspace{1cm} xi

Prologue: Big Scandals, Higher Prices \hspace{1cm} 1
A. Pharma under Fire \hspace{1cm} 1
B. A Note before We Begin \hspace{1cm} 12
C. The Strange Economics of Pharmaceuticals \hspace{1cm} 13
D. Generics – A Brief Primer \hspace{1cm} 19

Introduction: The Winding Road to Generic Entry \hspace{1cm} 26

1 “Generation 1.0”: The Rise and Fall of Traditional Pay-for-Delay \hspace{1cm} 34
A. The Basic Contours of Pay-for-Delay \hspace{1cm} 34
B. Pay-for-Delay as a Bottleneck to Entry \hspace{1cm} 38
C. Is Pay-for-Delay Actually Wrong? Pharma Heads to the Supreme Court \hspace{1cm} 41

2 “Generation 2.0”: Complicating Pay-for-Delay \hspace{1cm} 49
A. Already Steps Ahead of Actavis \hspace{1cm} 49
B. \textit{In re Lipitor}: Everything but the Kitchen Sink \hspace{1cm} 53
C. The Post-Actavis Landscape, Contract Clauses, and \textit{King Drug} \hspace{1cm} 56

3 “Generation 3.0”: New Tactics for Active Obstruction of Generics \hspace{1cm} 66
A. A New Generation of Pharmaceutical Delay \hspace{1cm} 66
B. Product Hopping and the Purple Pill \hspace{1cm} 69
C. New Examples of Product Hopping \hspace{1cm} 74
D. Scout’s Honor in Product Hopping \hspace{1cm} 78
Contents

4  “Generation 3.0”: Continued Obstruction of Regulatory Pathways  80
   A. REMS-Based Delay  80
   B. Delay via Citizen Petition  91
   C. Preventing the “Skinny Label”: Blocking Carve-Outs  102

5  Empirical Evidence of a Citizen’s Pathway Gone Astray  113
   A. Methodology  115
   B. Results  122
   C. The Road Ahead  131

Conclusion: A Call for Systematic Reform  137
   A. Societal Harms  138
   B. Systems, Simplification, Sunshine, and Standards-Based Doctrines  139

Index  145